Cagrilintide
Also known as: NN9838, CagriSema (when combined with semaglutide)
Last updated: 1/22/2026 Last reviewed: 1/22/2026
At a Glance
Cagrilintide is an investigational amylin-pathway therapy. It is frequently discussed in the context of combination therapy with semaglutide.
⚠️ Investigational drug: This compound is not approved for general clinical use. This page summarizes published research and does not provide medical advice or dosing recommendations.
Mechanism of Action (High Level)
Amylin receptor agonism is associated with appetite/satiety pathways and may complement incretin-based therapies in certain trial designs.
Evidence Summary
Moderate Confidence RCT ≤3 YearsA large trial evaluated cagrilintide + semaglutide in adults with overweight/obesity and type 2 diabetes. [PMID: 40544432]
Safety & Unknowns (High Level)
- As an investigational agent, long-term safety and generalizability depend on ongoing and future trials.
Key Studies
| Year | Type | Topic | Citation |
|---|---|---|---|
| 2025 | RCT | Cagrilintide + semaglutide in T2D with overweight/obesity | [PMID: 40544432] |
📚 See linked items in the Literature section.